In a recent work, we surveyed the status of the compounds tested against these and other epigenetic targets identified from ChEMBL, Therapeutic Target Database, and scientific literature. We found out that for 136 of these targets, there are more than ten reported inhibitors, which meant a considerable increase in comparison with the 52 targets fulfilling the same criteria in 2017. The rich structure-activity relationships (SAR) contained in these large data sets represents an excellent source of information to develop predictive models that have not been developed thus far on a large-scale basis. In a previous work the authors explored the SAR of epigenetic target data sets using the concept of activity landscape.